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Introduction
Benign prostatic hyperplasia (BPH) is occurred due to 
the proliferation of irregular connective tissue, glandular 
epithelium and smooth muscle in the prostate transition 
zone (1).
The disease involves tens of millions of elderly men in 
the world and as growing public health problem causes 
urinary retention (bladder outlet obstruction) (2).
Clinically, the disorder is diagnosed as lower urinary 
tract symptoms (LUTS) (3). Hence, the development of 
urinary tract symptoms is considered as BPH progression 
causing problems such as loss of quality of life of patients 
with acute urinary retention, recurrent infections of the 
urinary tract, urinary incontinence, calcium deposits 
in the bladder, kidney obstructive failure, BPH-related 
surgery (4) and probably threaten the patients’ life (5).
The treatment recommended preventing BPH progression 
was consisted of the combination of 5α-reductase 
inhibitors and α blocker (4). Tamsulosin is of the third 
generation of alpha-blockers and is regarded as one of 
the most frequent drugs used for BPH. Its long-term 
consumption is followed by complications such as 
orthostatic hypotension, dizziness, headache, asthenia, 
runny nose and ejaculation problems as well (4,6).
In recent years, the use of herbal medicines and natural 
products is increasing because of fewer side effects (7,8). 
Implication for health policy/practice/research/medical education:
Peganum harmala can be administered as a herbal remedy for improving urinary symptoms of benign prostate enlargement.
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Introduction: Benign prostatic hyperplasia (BPH) is considered as a major cause of lower 
urinary tract symptoms (LUTS) in older men and its most common sign is nocturia. 
Objectives: This study aimed to determine the effect of the seeds of Peganum harmala 
compared with tamsulosin on alleviating urinary symptoms in patients with BPH.
Patients and Methods: In this single blind clinical trial study, 90 patients diagnosed with 
BPH and LUTS, based on international prostate standard survey (IPSS) were divided into 
three groups. The first group was received oral capsule of P. harmala, the second group 
was administered tamsulosin with oral P. harmala seed and the third group was received 
tamsulosin drug and they were evaluated after 4 weeks. 
Results: The results showed that the difference between mean scores of IPSS was significant 
after the intervention (P = 0.001). Besides, the mean of IPSS in the three groups was significantly 
different (P = 0.001) (the first group 41.9 ± 5.3, the second group 21.0 ± 4.4 ,the third group 
16.5 ± 3.7 respectively). However, after the intervention, patients in the second group had 
the lowest average on most indicators of IPSS but the difference was only significant about 
urinary frequency, nocturia and intermittency(P < 0.05).
Conclusion: Application of Peganum harmala seed can be useful in reducing urinary 
symptoms in patients with BPH.
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On the other hand, effect of various herbal medicines on 
BPH and its associated complications has been reported in 
various studies (9-11).
Peganum harmala L. which belongs to Zygophyllaceae 
family, has long been focused in Iranian traditional 
medicine. P. harmala is a wild and perennial plant grown 
in a semi-arid, steppe regions and sandy soils in the 
Eastern Mediterranean region (12-14).
The seeds of this plant are rich in carbohydrates, lipids, 
proteins, minerals, alkaloids and amino acids. Active 
ingredients of this plant include mainly beta-carboline and 
quinazoline alkaloids that were particularly accumulated 
in its seeds and roots (14).
The properties of this plant were consisted of positive 
effects on cardiovascular disease, nervous system, 
gastrointestinal complications, bone, diabetes, immune 
system disorders, antimicrobial activity inducing abortion, 
anti-inflammatory, anti-cancer and anti-proliferative 
activities (14). However, it should be noted that excessive 
consumption of this herb and its illegal prescription 
can also cause various complications and toxicity in 
consumers (11).
Although diagnostic methods and new treatments for 
BPH management have been developed (15), there is no 
effective treatment with few side effects for this disorder.
Objectives
Given the importance of this plant in herbal medicine and 
limitations of clinical studies, this study was conducted 
to determine the effect of edible seeds of P. harmala on 
nocturia in patients with benign prostatic hyperplasia 
referred to urology clinic affiliated with Ayatollah-Kashani 
hospital in Shahrekord, Iran.
Patients and Methods
Subjects
This double-blind clinical trial study was carried out on 
90 patients diagnosed with benign prostatic hyperplasia 
based on international prostate standard survey (IPSS). 
Besides, criteria such as the size of the prostate, prostate-
specific antigen (PSA), history of previous disease, 
history of previous surgery were considered. Inclusion 
criteria were patients with benign prostatic hyperplasia. 
Exclusion criteria were patients who were candidate of 
surgery, obvious anatomic or functional anomaly in the 
urinary tract, thyroid disorder, prostate cancer, patients 
with mental disorders, active or chronic infections and 
sensitivity to the drug.
Patients were divided into three groups. The sampling 
method was random allocation.
The first group (32 patients) treated with oral capsules of 
P. harmala seed (containing one gram of Pe. harmala), 
the second group (29 patients) was received conventional 
therapy of alpha blockers (tamsulosin) in combination 
with oral administration of P. harmala and the third group 
(29 patients) were prescribed conventional therapy of 
alpha blockers (tamsulosin) alone. Therapeutic dose used 
in this study was 1 g. However, due to the hepatotoxicity 
effect of P. harmala, hepatic factors such as aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), 
and alkaline phosphatase (ALP) in all patients were 
checked and after 4 weeks were examined. 
Ethical issues
The research followed the tenets of the Declaration of 
Helsinki; informed consent was obtained, and the research 
was approved by the ethics committee of Shahrekord 
University of Medical Sciences. In this study, the full 
description of the processes and the importance of the study 
were explained to the participants who had volunteered 
and were selected (IRCT code# IRCT2014091419151N1, 
and ethical approval code# 92-5-4). 
Statistical analysis
The data were analyzed by SPSS 22 using descriptive tests, 
Kruskal-Wallis, Wilcoxon and Mann-Whitney U tests. 
A P value less than 0.05 was considered as statistically 
significant.
Results
In this study, 90 patients with benign prostatic 
hypertrophy were divided into three groups. Groups were 
not significantly different regarding to mean age, prostate 
size by ultrasound and PSA levels (P > 0.05).
Of the 90 patients, in P. harmala group 24 patients (75%), 
in tamsulosin and P. harmala group 24 (82.8 %) and in 
tamsulosin group 22 patients (75.9 %) had no previous 
medical history. The history of surgery was 27 (84.4%) 
in the P. harmala group, 26 (89.7%) in tamsulosin and P. 
harmala group. Twenty-six (89.7%) in tamsulosin group 
had no history of previous surgery.
The average size of the prostate in P. harmala group, P. 
harmala and tamsulosin group, and tamsulosin group 
was 25.81 ± 14.8 cm3, 25.71 ± 11.3 cm3, 75.03 ± 13.65cm3, 
respectively. The serum level of PSA in P. harmala group, 
P. harmala and tamsulosin group, and tamsulosin group 
was 1.37 ± 0.98 ng/mL, 1.64 ± 0.70 ng/mL, and 1.18 ± 0.77 
ng/mL respectively.
Scores distribution in the scoring questionnaire was not 
normal. Thus, to compare the scores of three groups 
before and after the intervention, the Kruskal-Wallis test 
was used. Before the intervention, there was no significant 
difference in the average of the three groups (P = 0.347), 
which indicated that the groups were matched. However, 
significant differences in mean scores after the intervention 
was detected (P = 0.001).
The lowest score of the questionnaire after the intervention 
in tamsulosin and P. harmala groups was 12.0 ± 4.4 and 
most score was related to tamsulosin group with 16.5 
± 3.7. 
Besides, it was shown that P. harmala and tamsulosin 
group with an IPSS  average of 12.0 ± 4.4, P. harmala 
with an IPSS average 14.9 ± 5.3 and tamsulosin group 
with an IPSS average of 16.5 ± 3.7 were significantly 
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different; however, P. harmala and tamsulosin group 
and tamsulosin group were not significantly different. 
In addition, it was indicated that in three groups before 
and after the intervention, mean scores were significantly 
different (P < 0.001; Table 1).
Assessment of the survey scores for all groups before and 
after the intervention showed that they had significant 
difference (P < 0.05) and variables including urinary 
frequency and nocturia after the intervention, respectively 
with (P = 0.002) and (P = 0.001) in each three groups were 
significantly different. There was a significant difference 
among three groups in terms of intermittency symptoms 
(P = 0.002; Table 2).
Discussion
This study examined the effect of P. harmala seed in 
benign prostatic hyperplasia. 
In this study, combination of P. harmala with tamsulosin 
had more effect on alleviating mean of urinary symptoms 
than other groups, although this difference was significant 
in some cases. Besides, patients in P. harmala group 
compared to the third group had more average reduction 
in urinary symptoms after the intervention. Despite the 
fact that in some studies P. harmala has been known as a 
diuretic herb (16), in this study, it was suggested that it had 
a positive effect on variables such as frequent urination of 
patients.
On the other hand, the mechanism of action of benign 
prostatic hyperplasia is unknown, however, some studies 
considered the following factors including oxidative 
stress (17) inflammation (5) and vasoconstriction (18) in 
the occurrence of the disease. It was shown that ethanol 
 Table 1. Comparison of IPSS before and after intervention in all three groups based on the total survey score
Tamsulosin group Peganum harmala and Tamsulosin group Peganum harmala group P value
Mean ± SD Mean ± SD Mean ± SD
Before intervention 22.6 ± 3.8 21.5 ± 3.6 21.2 ± 4.4 0.347
After intervention 16.5 ± 3.7 12.0 ± 4.4 14.9 ± 5.3 0.001
 P value < 0.001 < 0.001 < 0.001
Table 2. Comparison of IPSS before and after intervention in all three groups based on the survey questions
Groups
P valueGroups Peganum harmala 
group (Mean±SD)





Before 2.68 ± 1.89 2.93 ± 1.70 2.68 ± 1.58 0.826
After 2 ± 1.70 1.86 ± 1.30 2.27 ± 1.46 0.568
P value before and after intervention < 0.001 < 0.001 < 0.001
Urinary frequency
Before 3.65 ± 1 2.62 ± 1.42 3.51 ± 0.82 0.078
After 2.43 ± 1.01 1.68 ± 1.19 2.75 ± 0.91 0.002
P value before and after intervention < 0.001 < 0.001 < 0.001
Intermittency
Before 2.28 ± 1.3 2 ± 1.33 2.96 ± 1.14 0.094
After 1.93 ± 1.13 1.10 ± 0.85 2.17 ± 0.88 0.001
P value before and after intervention 0.008 < 0.001 < 0.001
Urgent need to urinate
Before 2.87 ± 1.56 2.82 ± 1.25 2.89 ± 1.17 0.98
After 1.96±1.06 1.86 ± 0.63 2.41 ± 0.98 0.057
P value before and after intervention < 0.001 < 0.001 < 0.001
Weak flow of urine
Before 3.56 ± 1.43 3.82 ± 1.03 4.10 ± 1.04 0.217
After 2.68 ± 1.37 2.34 ± 1.14 2.06 ± 1.06 0.141
P value before and after intervention < 0.001 < 0.001 < 0.001
Straining to urinate
Before 2.46 ± 1.07 3.20 ± 1.26 2.58 ± 1.45 0.128
After 1.81 ± 1.17 1.86 ± 1.21 2.96 ± 1.05 0.871
P value before and after intervention < 0.001 < 0.001 < 0.001
Nocturia
Before 3.68 ± 1.25 4.13 ± 0.91 3.86 ± 0.74 0.219
After 2.06 ± 1.13 1.34 ± 0.72 2.89 ± 0.72 0.001
P value before and after intervention < 0.001 < 0.001 < 0.001
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double publication) have been completely observed by the 
authors.
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